INCY
Incyte Corporation
NASDAQ · USHealthcareBiotechnology
$115.65-1.36%
Price as of Jul 20, 2026
INCY profitability
Incyte Corporation profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 92.5%
- EBITDA margin
- 34.9%
- EBIT margin
- 27.1%
- Net margin
- 26.7%
- Free cash flow margin
- 27.1%
Returns
- Return on equity
- 25.8%
- Return on assets
- 19.5%
- Return on invested capital
- 26.0%
- Asset turnover
- 0.75x
Cash efficiency
- Cash from operations
- $1.5B
- Cash per share
- $20
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.